

Retatrutide 40 mg

RT-2026-006 Lot BM40BL Analyzed October 7, 2026



TIMELINE

ORDERED

October 3, 2026

RECEIVED

October 5, 2026

ANALYZED

October 7, 2026

SAMPLE

NAME

Retatrutide 40 mg

EXPECTED

Retatrutide

AMOUNT

1 vial, lyophilized powder

TESTING

CLIENT

Flatirons Research Co

TEST TYPE

Content & purity

METHOD

HPLC-UV

CONTENT, HOW MUCH IS IN IT

49.60 mg

Label claim: 40 mg


PURITY, HOW CLEAN IT IS

>99%

by HPLC-UV peak area

CHROMATOGRAM

HPLC-UV



● 18.40 min, Retatrutide, >99%

ANALYST COMMENTS

White lyophilized powder, blue-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett

Lab Director, PuriLab Analytical

Analysis date: October 7, 2026

VERIFICATION CODE

RT-HR4F-CGXD

Verify at purilab.org/verify/RT-HR4F-CGXD

SCAN TO VERIFY



RT-HR4F-CGXD

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.